Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity (Q73521186)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

cost–benefit analysis

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

P E Slater

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

D Shouval

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

publication date

1 January 2001

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

published in

Journal of Hepatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

92-99

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

Prevention of viral hepatitis A: past, present and future

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Vaccination against hepatitis A: control 3 years after the first vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Hepatitis in day care centers: epidemiology and prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Type A viral hepatitis. New developments in an old disease

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

The need for liver transplantation: a nationwide estimate based on consensus review.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

The prevalence of hepatitis A antibodies among Israeli travellers and the economic feasibility of screening before vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Sibship size as a risk factor for hepatitis A infection

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Passive immunization against hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Immunoglobulin prophylaxis for hepatitis A

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Apparent effect of immune serum globulin prophylaxis in the military on viral hepatitis incidence in the civilian population in Israel

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Interruption of an outbreak of hepatitis A in two villages by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Use of hepatitis A vaccine in a community-wide outbreak of hepatitis A.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

An outbreak of hepatitis A in an intensive care unit.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Safety and immunogenicity of an inactivated hepatitis A vaccine: effect of dose and vaccination schedule

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Vaccines to prevent viral hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Long-term persistence of anti-HAV antibodies following active immunization with hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Safety and Immunogenicity of a High-Potency Inactivated Hepatitis A Vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Hepatitis A virus infection in households

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Above-average synthesis of anti-HAV by a booster effect after viral hepatitis A (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Usefulness of immune serum globulin in viral hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Discussion: who should receive hepatitis A vaccine? A strategy for controlling hepatitis A in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Who should receive hepatitis A vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Simultaneous vaccination for hepatitis A and B.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Administration of hepatitis A vaccine to a military population by needle and jet injector and with hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Clinical and immunological investigation of a new combined hepatitis A and hepatitis B vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Simultaneous vaccination against hepatitis A and B: results of a controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Persistence of vaccine-induced antibody to hepatitis A virus

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

An economic analysis of different strategies of immunization against hepatitis A virus in developed countries

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Cost effectiveness of hepatitis A prevention in France

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Is travel prophylaxis worth while? Economic appraisal of prophylactic measures against malaria, hepatitis A, and typhoid in travellers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Cost-effectiveness analysis of hepatitis A prevention in travellers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Cost-effectiveness analysis of vaccination against hepatitis A in travellers

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Recommendations for Prevention of Hepatitis A Based on a Cost-Effectiveness Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Cost effectiveness of hepatitis A virus immunisation in Spain

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

An economic evaluation of the introduction of vaccination against hepatitis A in a peacekeeping operation. The case of the United Nations Protection Force in Yugoslavia

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Should British soldiers be vaccinated against hepatitis A? An economic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Perspectives on the control of hepatitis A by vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Relapsing hepatitis A. Review of 14 cases and literature survey

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

Nosocomial hepatitis A.

1 reference

https://api.crossref.org/works/10.1016%2FS0168-8278%2800%2900007-6

7 January 2021

10.1016/S0168-8278(00)00007-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11211913%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference